Skip to content
Home/Companies/Biotech/GenSight Biologics
GB

GenSight Biologics

Biotech·France·Active

GenSight Biologics is a healthcare company, headquartered in France.

Entry
–
Hold
–
Status
Active
Est. EV
–

Who owns GenSight Biologics?

GenSight Biologics is currently owned by Sofinnova Partners through Sofinnova Crossover Fund I (2018 vintage). Across its history, GenSight Biologics has been through 2 private equity ownership periods, detailed in the timeline below.

Hand-verified · updated 2026-04-21

Sofinnova Partners
Most recent investor
Sofinnova Partners
Sofinnova Crossover Fund I · 2018 · VC
2 ownership periods · full history below

Key facts

HQFrance
SectorHealthcare

Ownership history

2 ownership periods

Active
Currently held by Sofinnova Partners.
Abingworth
AbingworthExited 2016
2014 · 2016 · Abingworth Bioventures VI · 2014 · Life Sciences VC
IPO
MOIC
–
Sofinnova Partners
Sofinnova PartnersActive
present · Sofinnova Crossover Fund I · 2018 · VC
MOIC
–

More from Sofinnova Crossover Fund I

Other portfolio companies in the same fund.

Amolyt Pharma
Exited 2024
BiotechFrance· 2021
to
Sphere Bio (formerly Sphere Fluidics)
Exited 2025
MedTechUnited Kingdom· 2021
to
Artios Pharma
Active
BiotechUK· 2020
Calliditas
Exited 2024
BiotechSweden· 2020
to
Hemab Therapeutics
Active
BiotechDenmark· 2020
F2G
Active
BiotechUK· 2019

More PE-backed in Biotech

Comparable biotech deals from other GPs.

InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
2NA FISH
Active
Gruenderfonds RuhrGermany· 2026
Data refreshed weekly · Sourced from public filings